QUECTEL-WIRELESS
14.11.2022 09:01:38 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces its expanded Wi-Fi module portfolio with the launch of the FC6xE series of Wi-Fi/Bluetooth modules, based on Qualcomm’s QCA206x Wi-Fi 6E chip. Designed to deliver faster, more secure, and more robust Wi-Fi experiences than ever before, the FC6xE also features Bluetooth audio functionality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221113005138/en/
Quectel announces extended Wi-Fi 6/6E module portfolio to address home and commercial environments (Photo: Business Wire)
Supporting 2 × 2 MIMO and DBS, the FC6xE family provides a maximum data rate up to 3000 Mbps. With a compact and unified form factor of 19.9 mm × 18.0 mm × 2.1 mm, the FC6xE modules are the optimal Wi-Fi/Bluetooth solution for size-sensitive applications and can help customers reduce product size and optimize application design cost.
“Targeting the nascent Wi-Fi 6/6E market, the FC62E, FC64E, FC65E and FC66E all offer superior Wi-Fi 6/6E performance,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "When used in combination with Quectel 5G modules, they also deliver best-in-class 5G functionality, guaranteeing ultra-reliable connections for a wide range of multi-user scenarios including smart homes, shopping malls, schools and factories.”
The modules join an already extensive range of Wi-Fi/Bluetooth modules delivering functionality across Wi-Fi 4, Wi-Fi 5, Wi-Fi 6, and Wi-Fi 6E.
RF Wi-Fi/Bluetooth modules
- FC20/21 - typically used in connecting with different Linux/Android application processors, the compact form factor, low power consumption, extended temperature range and stable SDIO interface allow this module to serve a wide range of IoT applications including consumer, safety, industrial, mobile hotspots and healthcare.
- FC80A - a high-performance Wi-Fi 5 module, supporting 2.4GHz and 5GHz RSDB (Real simultaneous dual band) and Bluetooth 5.1, the FC80A can meet the Wi-Fi & Bluetooth application design requirements expected across consumer fields including set top boxes and VR.
- FC909A - with a reliable SDIO 2.0 interface enabling WLAN capability, the FC909A also provides BT functions with low power consumption, making it ideal for mobile devices requiring battery powered and compact size.
MCU Wi-Fi/Bluetooth Modules
- FC41D - Based on a standalone Wi-Fi & Bluetooth chip, the FC41D can offer diversified applications for customers. Combined with its ultra-compact size, low power consumption, ultra-wide temperature range and high reliability, FC41D can meet the requirements of low flow control and data acquisition applications such as smart homes and industrial control.
The hosted range of Wi-Fi/Bluetooth modules are ideal for both home and commercial applications including set top boxes, smart TVs, and smart speakers in the home and POS, scanner, and printer applications in a business environment. The hosted range is also appropriate for a wide range of telematics applications. The MCU Wi-Fi/Bluetooth module is typically used as a connectivity link between IoT devices and public or private cloud.
Complementing the FC6xE modules are a range of antennas across the 2.4Ghz and 6Ghz spectrum including the YF0026AA FPC, YF0027AA FPC, YF0023AA FR4 and YEWT004AA while additional antennas can support 5Ghz spectrum.
For more information on the Quectel range of Wi-Fi/Bluetooth modules, head over to our website: https://www.quectel.com/wifi-iot-modules
For more information on Quectel antennas: https://www.quectel.com/product-category/antennas
Download our Wi-Fi 6 white paper: https://www.quectel.com/library/wifi-6-white-paper
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom